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Significance of this study
What is already known about this subject?
 ► Randomized trials and comparative effectiveness
studies of metformin versus sulfonylurea use for
oral diabetes treatment have demonstrated conflict-
ing results regarding their relative safety.
 ► There is specific concern about harms of sulfony-
lureas in individuals with pre-existing coronary ar-
tery disease, who may be more susceptible to direct
cardiotoxic effects or hypoglycemia from sulfony-
lurea use.
What are the new findings?
 ► Sulfonylurea monotherapy was common during the
study period (2005–2015) in a population of indi-
viduals with type 2 diabetes, reasonably controlled
glycemia (hemoglobin A1c ≤58 mmol/mol), and ob-
structive coronary artery disease.
 ► In the study population, treatment with sulfonylureas 
was associated with greater 2-year all-cause mor-
tality than treatment with non-sulfonylurea medica-
tions or no diabetes medications, but the association 
was not statistically significant in fully adjusted sur-
vival analysis.
 ► There was no difference in 2-year all-cause mor-
tality between individuals treated with non-sulfony-
lurea medications and those not taking a diabetes
medication.
How might these results change the focus of 
research or clinical practice?
 ► In individuals with reasonably controlled type 2 dia-
betes and obstructive coronary artery disease, oral
diabetes monotherapy with non-sulfonylurea med-
ications (especially metformin) may be associated
with lower short-term mortality than treatment with
sulfonylureas.
AbStrAct
Objective To determine whether sulfonylurea use, 
compared with non-sulfonylurea oral diabetes 
medication use, was associated with 2-year mortality in 
individuals with well-controlled diabetes and coronary 
artery disease (CAD).
Research design and methods We studied 5352 
US veterans with type 2 diabetes, obstructive CAD on 
coronary angiography, hemoglobin A1c ≤7.5% at the 
time of catheterization, and taking zero or one oral 
diabetes medication (categorized as no medications, 
non-sulfonylurea medication, or sulfonylurea). We 
estimated the association between medication 
category and 2-year mortality using inverse probability 
of treatment-weighted (IPW) standardized mortality 
differences and IPW multivariable Cox proportional 
hazards regression.
Results 49%, 35%, and 16% of the participants 
were on no diabetes medications, non-sulfonylurea 
medications, and sulfonylureas, respectively. In 
individuals on no medications, non-sulfonylurea 
medications, and sulfonylureas, the unadjusted mortality 
rates were 6.6%, 5.2%, and 11.9%, respectively, and 
the IPW-standardized mortality rates were 5.9%, 6.5%, 
and 9.7%, respectively. The standardized absolute 
2-year mortality difference between non-sulfonylurea
and sulfonylurea groups was 3.2% (95% CI 0.7 to
5.7) (p=0.01). In Cox proportional hazards models, the
point estimate suggested that sulfonylurea use might
be associated with greater hazard of mortality than
non-sulfonylurea medication use, but this finding was
not statistically significant (HR 1.38 (95% CI 1.00 to
1.93), p=0.05). We did not observe significant mortality
differences between individuals on no diabetes
medications and non-sulfonylurea users.
Conclusions Sulfonylurea use was common
(nearly one-third of those taking medications) and
was associated with increased 2-year mortality in
individuals with obstructive CAD. The significance of the
association between sulfonylurea use and mortality was
attenuated in fully adjusted survival models. Caution
with sulfonylurea use may be warranted for patients
with well-controlled diabetes and CAD, and metformin
or newer diabetes medications with cardiovascular
safety data could be considered as alternatives when
individualizing therapy.
InTROduCTIOn
Individuals with type 2 diabetes mellitus and 
cardiovascular disease are at an elevated 
risk of cardiovascular events and mortality, 
but may also be at risk for overtreatment.1 2 
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While several new diabetes medications have demon-
strated cardiovascular benefits,3–7 the vast majority of 
individuals with diabetes and lower hemoglobin A1c 
(HbA1c) levels are on older oral medications (eg, 
metformin, sulfonylureas) for which specific cardio-
vascular outcomes trials have not been performed. 
Several observational studies and randomized trials 
have compared metformin and sulfonylurea therapy 
in patients with diabetes.8–15 While most have demon-
strated better outcomes with metformin treatment, the 
studies vary methodologically and in quality,8 15 and 
sulfonylurea use remains very common.16 17 One area 
of uncertainty is whether improved outcomes associ-
ated with metformin compared with sulfonylurea use 
are attributable to the benefits of metformin or harms 
related to sulfonylureas.8 Individual studies, meta-anal-
yses, and review articles arrive at conflicting conclu-
sions, and a clear consensus has not emerged.8–15
The American Diabetes Association advocates an 
individualized approach to diabetes management that 
incorporates patient preferences, comorbidities, and 
diabetes complications.18 19 However, the interactions 
between medication efficacy, safety, and comorbid 
conditions are not addressed in prospective trials. For 
ethical reasons, randomized trials do not compare 
harms of treatment as their primary objective, and they 
are often not powered to detect harms of treatment as 
secondary outcomes if drug-related adverse events occur 
infrequently. As such, observational studies, particu-
larly those derived from clinical data sets, are neces-
sary to evaluate treatment-related harms, although care 
must be taken to avoid bias. In addition, randomized 
trials are not well suited to provide evidence for indi-
vidualized or stratified treatment approaches that apply 
to specific subgroups but not to the entire population 
of patients with a disease.20–22 Studies are needed that 
focus on specific patient populations to support an indi-
vidualized approach to diabetes care. With regard to 
cardiovascular safety of older oral diabetes treatments, 
few studies have specifically examined these medica-
tions in individuals with known coronary artery disease 
(CAD) in whom cardiovascular harms may be more 
readily apparent.23 24 In addition, prior studies have not 
focused on individuals with well-controlled glycemia, 
a patient population that may be at increased risk of 
hypoglycemia or overtreatment,2 for whom providers 
may have greater flexibility with diabetes treatment 
choice, and in whom minimizing harm from diabetes 
treatment is an important goal.
Accordingly, the aim of this study was to assess the 
association between sulfonylureas, non-sulfonylurea 
oral treatments, and no diabetes medications and short-
term mortality in individuals with objectively confirmed 
CAD and well-controlled diabetes. Elucidating the 
comparative effects of the most commonly used oral 
diabetes medications on short-term clinical outcomes 
in individuals with CAD could inform diabetes medica-
tion optimization at the time of a myocardial infarction 
(MI) or percutaneous coronary intervention in individ-
uals at high risk of short-term mortality.
MeTHOds
study population
We used data from the US Veterans Affairs (VA) Clinical 
Assessment, Reporting, and Tracking Program (CART), 
a database of US veterans who have undergone cardiac 
catheterization since 2005.25 Patient and procedural data 
in CART can be merged with longitudinal VA patient 
data, including pharmacy data, laboratory testing, 
procedure codes, diagnosis codes, and vital status. For 
this study, we included individuals in CART with type 2 
diabetes, based on a previously validated algorithm using 
VA data.26 Briefly, we included patients with one (from 
an inpatient encounter) or two (from outpatient encoun-
ters)  InternationalClassification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) diagnosis codes 
for type 2 diabetes occurring within a 24-month period 
prior to presentation for cardiac catheterization, or with 
a filled prescription for a diabetes medication.26
In this analysis, we focused on individuals with well-con-
trolled type 2 diabetes using simple diabetes regimens, 
for whom there may be greater flexibility with medica-
tion choice and who may face a real risk of harm from 
certain treatments. Accordingly, we defined well-con-
trolled glycemia as having an HbA1c ≤58 mmol/mol 
(7.5%) within 6 months prior to catheterization, and we 
limited our study to those taking zero or one oral diabetes 
medication at the time of catheterization. As we were 
interested in addressing the safety and/or benefits of 
sulfonylureas and other diabetes medications specifically 
in high-risk individuals with cardiovascular disease, we 
included individuals who underwent catheterization for 
acute coronary syndrome (ST elevation MI, non-ST eleva-
tion MI, unstable angina) or who had obstructive CAD 
on elective angiography. Obstructive CAD was defined as 
any stenosis ≥50% in the left main coronary artery and/
or ≥70% in any other coronary artery.
exposure
The primary exposure was diabetes medication category 
at the time of presentation with MI or for angiography 
(no medications, non-sulfonylurea, or sulfonylurea). 
We determined baseline medication category by exam-
ining prescription data over 90 days prior to the date 
of catheterization. Individuals with a filled prescription 
for either a non-sulfonylurea or sulfonylurea medi-
cation in the 90 days preceding catheterization were 
considered exposed, and individuals with a prescription 
for more than one diabetes medication within 90 days 
of catheterization were excluded. To be categorized as 
on no medications, individuals had to have no filled 
prescriptions for any diabetes medication in the 90 days 
prior to catheterization. The 90-day window for a medi-
cation prescription was chosen as this is the maximum 
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duration that is typically covered or dispensed for a 
single prescription in the VA.
Outcome
The primary outcome was 2-year all-cause mortality 
based on VA vital status data. VA vital status data integrate 
multiple VA and non-VA data sources, including the VA 
Beneficiary Identification Records Locator Subsystem 
Death File, VA Medicare Vital Status File, and the Social 
Security Administration Death Master File. We focused 
on short-term mortality for two reasons. First, there is 
greater opportunity for bias in the estimated association 
between baseline medication exposure and outcomes 
as the follow-up time increases. Second, the period of 
time around the performance of coronary angiography 
represents an opportunity for diabetes treatment modi-
fication or optimization. Estimating the association 
between diabetes treatment at the time of CAD diagnosis 
and a near-term clinical outcome provides the best obser-
vational evidence for treatment modification at the time 
of cardiac catheterization or acute coronary syndrome.
statistical analysis
We compared baseline characteristics between medi-
cation groups using χ2 tests for categorical variables 
and Mann-Whitney-Wilcoxon tests for continuous and 
ordinal variables. We plotted unadjusted Kaplan-Meier 
survival curves after cardiac catheterization for each 
medication category, and compared survival probability 
with the log-rank test.
We used generalized boosted regression (R V.3.1, 
TWANG package)27 to estimate propensity scores for 
medication category based on demographics (age, sex, 
race), CAD risk factors (family history of CAD, tobacco 
use, hypertension, hyperlipidemia, body mass index, 
Framingham cardiovascular disease risk score), comor-
bidities (peripheral arterial disease, congestive heart 
failure, chronic obstructive pulmonary disease, chronic 
kidney disease (CKD), dialysis, depression, post-trau-
matic stress disorder), angiography-related variables 
(indication for catheterization, postangiography revas-
cularization), and diabetes-related variables (baseline 
HbA1c, diabetes duration). CKD was based on indica-
tion as a pre-existing problem on the standardized CART 
cardiac catheterization assessment or the presence of one 
inpatient or two outpatient ICD-9-CM diagnosis codes for 
CKD occurring within 2 years prior to the date of cardiac 
catheterization. Generalized boosted regression differs 
from standard approaches to estimate propensity scores 
in that it applies an iterative process with multiple regres-
sion trees to fit complex and non-linear functions between 
treatment and covariates to identify the propensity score 
model that yields the best covariate balance between 
treatment groups, including more than two groups as in 
the current study, while avoiding overfitting.27 Because 
site-level effects cannot be accounted for in the TWANG 
package for generalized boosted regression, we exam-
ined variation in treatment and mortality across VA sites 
as a potential source of residual confounding. To address 
this issue, we assessed whether mortality in our data set 
varied across VA sites, which did not (online supplemen-
tary material figure 1). In addition, we performed a sensi-
tivity analysis in which we excluded the three VA sites 
(Las Vegas, Nevada; Temple, Texas; and Wilkes-Barre, 
Pennsylvania) where there were no individuals taking 
sulfonylurea medications.
We next used the estimated propensity of treatment 
from generalized boosted regression to generate an 
inverse probability of treatment-weighted (IPW) study 
population. We evaluated covariate balance before and 
after IPW using standardized differences; all covariates 
were adequately balanced (absolute difference <10%) 
except for CKD and dialysis. Therefore, we included CKD 
and dialysis as covariates in the primary analyses, and we 
performed a sensitivity analysis in which we excluded 
participants with CKD or on dialysis to achieve better 
confounder balance between medication categories.
We estimated the association between medication 
category and 2-year mortality using IPW-standardized 
mortality rates and absolute risk differences between 
medication categories. Secondarily, we used IPW multi-
variable Cox proportional hazards regression to esti-
mate the association between medication category and 
relative hazard of mortality. All analyses were conducted 
in SAS V.9.4 and R V.3.1 (R Foundation for Statistical 
Computing, Vienna, Austria). All statistical codes are 
available on request.
ResulTs
Of 5352 participants, 2603 (49%), 1889 (35%), and 
860 (16%) were on no diabetes medications, non-sul-
fonylurea medications, and sulfonylureas, respectively. 
Prior to inverse probability of treatment weighting, 
there were statistically significant differences between 
medication categories across most covariates (table 1). 
Individuals on non-sulfonylurea medications were less 
likely to have congestive heart failure, CKD, or be on 
dialysis compared with those on no diabetes medica-
tions or taking a sulfonylurea. After IPW, covariates 
were well balanced between medication categories; the 
standardized absolute difference between medication 
categories was <10% for all covariates except for CKD 
and dialysis (table 2).
Among those on non-sulfonylurea medications, 95% 
were on metformin, 3% were on pioglitazone or rosiglita-
zone, and <1% were on other medications. Among those 
taking a sulfonylurea, 69.2% were on glipizide, 30.2% 
were on glyburide, and 0.6% were on glimepiride. Partic-
ipants in each treatment category tended to remain in 
that category over the first year after cardiac catheteriza-
tion. Of the participants on no diabetes medications at 
baseline, 85.3% remained on no medications at 1 year 
after catheterization; 94.0% of those on non-sulfonylurea 
medication at baseline remained on monotherapy with 
a non-sulfonylurea medication at 1 year; and 85.0% of 
those treated with a sulfonylurea at baseline continued 
4 BMJ Open Diab Res Care 2018;6:e000516. doi:10.1136/bmjdrc-2018-000516








Age (years), mean (SD) 67.1 (8.0) 68.8 (8.8) 65.5 (7.2) 67.8 (8.1) <0.0001
Male, n (%) 5277 (98.6) 2568 (98.7) 1854 (98.2) 855 (99.4) 0.03
Race, n (%)
 White 4473 (83.6) 2142 (82.3) 1631 (86.3) 700 (81.4) 0.0002 
 Black 750 (14.0) 395 (15.2) 213 (11.3) 142 (16.5)
 Asian 32 (0.6) 18 (0.7) 13 (0.7) 1 (0.1)
 Pacific Islander 61 (1.1) 24 (0.9) 25 (1.3) 12 (1.4)
 Native American 36 (0.7) 24 (0.9) 7 (0.4) 5 (0.6)
Family history of CAD, n (%) 964 (18.0) 449 (17.3) 379 (20.1) 136 (15.8) 0.01
Tobacco, n (%) 318 (59.4) 1559 (59.9) 1137 (60.2) 484 (56.3) 0.1
Hypertension, n (%) 4986 (93.2) 2403 (92.3) 1764 (93.4) 819 (95.2) 0.01
Hyperlipidemia, n (%) 4907 (91.7) 2373 (91.2) 1756 (93.0) 778 (90.5) 0.04
BMI (kg/m2), mean (SD) 31.2 (5.5) 31.2 (5.9) 31.6 (5.5) 30.9 (5.4) <0.0001
Framingham risk score, mean (SD) 22.8 (11.2) 23.8 (11.4) 21.6 (10.4) 23.3 (11.5) <0.0001
PAD, n (%) 984 (18.4) 488 (18.8) 305 (16.2) 191 (22.2) 0.0006
CHF, n (%) 739 (13.8) 396 (15.2) 173 (9.2) 170 (19.8) <0.0001
COPD, n (%) 930 (17.4) 476 (18.3) 301 (15.9) 153 (17.8) 0.1
CKD, n (%) 960 (17.9) 524 (20.1) 128 (6.8) 308 (35.8) <0.0001
Dialysis, n (%) 147 (2.8) 106 (4.1) 3 (0.2) 38 (4.4) <0.0001
Depression, n (%) 1461 (27.3) 702 (27.0) 556 (29.4) 203 (23.6) 0.006
PTSD, n (%) 931 (17.4) 434 (16.7) 373 (19.8) 124 (14.4) 0.001
Presentation, n (%)
 Stable angina 210 (3.9) 112 (4.3) 72 (3.8) 26 (3.0) 0.001 
 Positive functional study 1290 (24.3) 611 (23.5) 427 (22.6) 252 (29.3)
 Ischemic heart disease 470 (8.8) 246 (9.5) 152 (8.1) 72 (8.4)
 Chest pain 3242 (60.6) 1558 (59.9) 1191 (63.1) 493 (57.3)
 Acute coronary syndrome 140 (2.6) 76 (2.9) 47 (2.5) 17 (2.0)
Postangiography revascularization, n (%) 
 None 2361 (44.1) 1160 (44.6) 794 (42.0) 407 (47.3) 0.02 
 PCI 1763 (32.9) 878 (33.7) 620 (32.8) 265 (30.8)
 CABG 1228 (22.9) 565 (21.7) 475 (25.2) 188 (21.9)









Baseline HbA1c category, n (%)
 <42 mmol/mol (<6%) 1055 (19.7) 625 (24.0) 287 (15.2) 143 (16.6) <0.0001 
 42–47 mmol/mol (6%–6.4%) 1634 (30.5) 846 (32.5) 570 (30.2) 218 (25.4)
 48–52 mmol/mol (6.5%–6.9%) 1540 (28.8) 692 (26.6) 603 (31.9) 245 (28.5)
 53–57 mmol/mol (7%–7.4%) 1123 (21.0) 440 (16.9) 429 (22.7) 254 (29.5)
Diabetes duration (years), mean (SD) 3.7 (2.71) 3.8 (3.0) 3.4 (2.4) 3.9 (2.4) <0.0001
BMI, body mass index; CABG, coronary artery by pass graft; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic 
kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c; PAD, peripheral arterial disease; PCI, percutaneous 
coronary intervention; PTSD, post-traumatic stress disorder.
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to be treated with just a sulfonylurea at 1 year after 
catheterization.
The unadjusted 2-year mortality rates were 6.6%, 5.2%, 
and 11.9% in the no medications, non-sulfonylurea, 
and sulfonylurea categories, respectively (p<0.0001 
for unadjusted between-group differences in mortality 
rate; table 3 and figure 1A). Among sulfonylurea users, 
mortality rates differed non-significantly between those 
taking glyburide and those taking other sulfonylureas 
(8.8% and 13.1% in those taking glyburide and other 
sulfonylureas, respectively; p=0.07; online supplemen-
tary tables 1 and 2). IPW-standardized 2-year mortality 
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Table 2  Covariate balance between medication 














 White 13.8 5.2
 Black 15.6 5.7
 Asian 8.1 8.1
 Pacific Islander 4.1 2.4
 Native American 8.4 4.5


















 Stable angina 6.9 7.5
 Positive functional 
study
15.7 4.2
 Ischemic heart 
disease
5.9 1.7
 Chest pain 13.8 2.0
Postangiography 
revascularization
 None 10.7 4.6
 PCI 6.2 3.5
 CABG 8.0 4.2
Baseline HbA1c 32.4 4.8
Diabetes duration 16.6 5.3
BMI, body mass index; CABG, coronary artery bypass graft; 
CAD, coronary artery disease; CHF, congestive heart failure; CKD, 
chronic kidney disease; COPD, chronic obstructive pulmonary 
disease; HbA1c, hemoglobin A1c; PAD, peripheral arterial disease; 
PCI, percutaneous coronary intervention; PTSD, post-traumatic stress 
disorder.
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rates were 5.9% (95% CI 5.0 to 6.9), 6.5% (95% CI 5.1 to 
7.9), and 9.7% (95% CI 7.7 to 11.8) in the no medica-
tions, non-sulfonylurea, and sulfonylurea categories, 
respectively (p<0.0001 for adjusted between-group 
differences in mortality rate). The absolute mortality 
difference between non-sulfonylurea and sulfonylurea 
groups was 3.2% (95% CI 0.7 to 5.7) (p=0.01; table 4). 
After IPW standardization, the absolute mortality differ-
ence between the no medication and non-sulfonylurea 
medication categories was non-significant (−0.6% (95% 
CI −2.2 to 1.1), p=0.5).
In secondary analysis, we used the IPW Cox propor-
tional hazards models to estimate relative hazards of 2-year 
mortality across the different medication categories. In 
the IPW Cox proportional hazards models, the overall 
type 3 test for variation in hazard of mortality across all 
three medication categories was non-significant (p=0.07). 
In pairwise comparisons between medication categories, 
sulfonylurea use showed a non-significant trend toward 
greater hazard of mortality compared with non-sulfony-
lurea medication use (HR 1.38 (95% CI 1.00 to 1.93), 
p=0.05; table 4 and figure 1C), whereas mortality risk was 
clearly comparable in those on no medications relative to 
non-sulfonylurea users (HR 1.02 (95% CI 0.77 to 1.35), 
p=0.9; table 4 and figure 1C).
We performed two sensitivity analyses to address 
possible sources of residual confounding. First, we 
excluded all participants (a total of 43 individuals) who 
underwent cardiac catheterization at sites where there 
were no patients in the sulfonylurea category, and this 
had no effect on the primary results (online supple-
mentary table 3). Second, we repeated the analyses after 
excluding patients with CKD or who use dialysis (a total 
of 964 individuals) as these variables are independent 
predictors of mortality, are more prevalent among those 
using sulfonylureas than among those in the other two 
medication categories, and remained unbalanced across 
medication categories even in the IPW study population. 
When excluding patients with CKD or dialysis use, the 
incidence rate of mortality declined in all three medica-
tion categories (table 3), but the pattern of unadjusted 
association with survival was similar to that observed in 
the full cohort (figure 1C). Individuals taking non-sulfo-
nylurea medications had the lowest unadjusted mortality 
rate, followed by those on no diabetes medications, with 
those taking sulfonylureas having the highest mortality 
(table 3 and figure 1C). The IPW-standardized 2-year 
mortality rates after excluding individuals with CKD or 
on dialysis were 4.7% (95% CI 3.7 to 5.6), 5.5% (95% 
CI 4.4 to 6.7), and 8.4% (95% CI 5.9 to 10.9) in the no 
medications, non-sulfonylurea, and sulfonylurea cate-
gories, respectively (table 4). The absolute mortality 
difference between non-sulfonylurea and sulfonylurea 
groups remained significant (IPW-standardized risk 
difference of 2.9% (95% CI 0.1 to 5.6), p=0.04; table 4), 
and the relative risk of mortality associated with sulfony-
lurea use compared with non-sulfonylurea medication 
use increased slightly (HR 1.52 (95% CI 1.04 to 2.21), 
p=0.03; table 4). As in the full cohort, mortality did not 
differ significantly between individuals on no diabetes 
medications and those taking a non-sulfonylurea medi-
cation (IPW-standardized risk difference of −0.9 (95% 
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Table 3  Crude mortality rates across diabetes medication categories in the full study cohort and after excluding individuals 
with chronic kidney disease or on dialysis
All participants No medications
Non-sulfonylurea 
users Sulfonylurea users
Full cohort 371/5352 (6.9%) 171/2603 (6.6%) 98/1889 (5.2%) 102/860 (11.9%)
Excluding participants with 
chronic kidney disease or on 
dialysis
244/4388 (5.6%) 106/2076 (5.1%) 86/1760 (4.9%) 52/552 (9.4%)
Epidemiology/Health Services Research
CI −2.4 to 0.6), p=0.24; HR 1.03 (95% CI 0.76 to 1.38), 
p=0.87; table 4).
dIsCussIOn
In this study, we found that sulfonylurea use was asso-
ciated with greater 2-year mortality in individuals with 
well-controlled diabetes and obstructive CAD compared 
with other oral diabetes medications or no treatment. 
In fully adjusted survival analysis, mortality differences 
between sulfonylurea and non-sulfonylurea users did not 
achieve statistical significance; therefore, mortality differ-
ences across medication categories could be attributed 
to confounding by risk factors for mortality. However, 
the results of our study suggest caution with sulfony-
lurea use in individuals with well-controlled diabetes 
and CAD for two reasons. First, in sensitivity analysis 
excluding individuals with CKD and dialysis—covariates 
that remained poorly matched after IPW—the mortality 
difference between sulfonylurea users and non-sulfony-
lurea users was statistically significant. Second, the point 
estimate for the association between sulfonylurea use 
and mortality, compared with non-sulfonylurea use, was 
substantial—38% higher, although the result was not 
statistically significant owing to wide CIs. We also found 
that sulfonylurea use was common in our study popu-
lation, 16% of all participants and 31% of those taking 
medications, consistent with prior studies in non-VA 
populations,16 17 suggesting that oral diabetes treatment 
optimization might impact a substantial proportion of 
individuals with diabetes and CAD. By limiting the study 
to individuals with well-controlled diabetes, we conclude 
that differences in mortality between treatment groups 
are unlikely to be explained by differences in levels of 
glycemic control. By focusing on 2-year mortality, our 
results suggest that active diabetes treatment optimiza-
tion at the time of MI or cardiac catheterization could 
impact short-term clinical outcomes, even after HbA1c-
based glycemic control goals have been achieved.
As diabetes management guidelines have increasingly 
focused on individualization of treatment, evidence to 
support tailoring treatment is needed. By focusing on a 
well-defined high-risk population of patients with diabetes 
and CAD, and by examining short-term outcomes, our 
study complements and extends the findings of prior 
trials and comparative effectiveness studies of metformin 
and sulfonylureas for diabetes treatment.8–11 14 24 Our 
results support the findings of a small randomized trial 
that found improved 5-year mortality outcomes associated 
with metformin treatment compared with sulfonylurea 
treatment in individuals with diabetes and CAD.24 On 
the other hand, our results contrast with those of a study 
of individuals with diabetes hospitalized with acute MI, 
which showed that individuals treated with sulfonylureas 
had lower in-hospital mortality than those on no diabetes 
medications or on regimens that did not include a sulfo-
nylurea.28 This difference may be explained by the fact 
that our study and the prior study of patients with acute 
MI focused on very different clinical outcomes—2-year 
mortality versus in-hospital mortality. In addition, most 
of the individuals in the sulfonylurea-treated group in the 
prior study were also taking additional diabetes medica-
tions, so whether the association with mortality was attrib-
utable to sulfonylureas or to a combination treatment 
approach is unclear.28
Both the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE)29 and Thiazolidinediones Or Sulfony-
lureas and Cardiovascular Accidents.Intervention Trial 
(TOSCA.IT)30 randomized trials evaluated sulfonylureas 
as add-on therapy to other diabetes medications, and 
neither study observed higher mortality with sulfony-
lurea use. Most, if not all, participants in the ADVANCE 
and TOSCA.IT studies were on multiple diabetes medi-
cations. Although gliclazide was the principal study drug 
employed in those randomized to intensive rather than 
standard glycemic treatment in ADVANCE, nearly 60% 
of participants in the standard glycemic control arm were 
on a sulfonylurea during follow-up, and most partici-
pants were on additional diabetes medications (70% on 
metformin, 24%–40% on insulin).29 In TOSCA.IT, indi-
viduals with HbA1c 53–75 mmol/mol (7%–9%) despite 
metformin treatment were randomized to receive either 
pioglitazone or a sulfonylurea; therefore, the primary 
treatment contrast was between sulfonylureas and piogli-
tazone.30 Thus, the designs of the ADVANCE and TOSCA.
IT studies make it difficult to make any inferences about 
the comparative safety of monotherapy with sulfony-
lureas and other oral diabetes treatments in individuals 
with underlying CAD.
The results of our study also contrast with the results 
of the Bypass Angioplasty Revascularization Investiga-
tion 2 Diabetes (BARI-2D) study that compared medical 
versus revascularization approaches for treatment of 
CAD, and insulin sensitization (primarily metformin 
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Figure 1  Unadjusted and adjusted survival after cardiac catheterization in individuals on no diabetes medications, taking 
non-sulfonylurea oral diabetes medication, and sulfonylureas. Unadjusted survival and the number at risk in each medication 
category are shown for the full study cohort (A); adjusted survival probabilities from multivariable Cox proportional hazards 
models comparing individuals in each medication category are shown in (B). Unadjusted survival and the number at risk in 
each medication category after excluding individuals with chronic kidney disease or on dialysis are shown in (C).
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Table 4  Association between baseline diabetes medication category and 2-year mortality
Adjusted mortality 
rate*  (95% CI)
Risk difference 
(95% CI) P values HR† (95% CI) P values
Full cohort
 Non-sulfonylurea 6.5% (5.1 to 7.9) Ref Ref Ref Ref
 Sulfonylurea 9.7% (7.7 to 11.8) 3.2 (0.7 to 5.7) 0.01 1.38 (1.00 to 1.93) 0.05
 No medications 5.9% (5.0 to 6.9) −0.6 (−2.2 to 1.1) 0.5 1.02 (0.77 to 1.35) 0.9
Excluding participants with CKD 
or on dialysis
 Non-sulfonylurea 5.5% (4.4 to 6.7) Ref Ref Ref Ref
 Sulfonylurea 8.4% (5.9 to 10.9) 2.9 (0.1 to 5.6) 0.04 1.52 (1.04 to 2.21) 0.03
 No medications 4.7% (3.7 to 5.6) −0.9 (−2.4 to 0.6) 0.24 1.03 (0.76 to 1.38) 0.87
*All-cause mortality rate in each medication category in the inverse probability of treatment-weighted population.
†HR for 2-year mortality in individuals taking sulfonylureas or no medications compared with those taking non-sulfonylurea medication in 
inverse probability of treatment-weighted Cox proportional hazards models additionally adjusted for chronic kidney disease and dialysis.
CKD, chronic kidney disease ref, reference.
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or thiazolidinedione therapy) versus insulin provision 
(primarily sulfonylurea or insulin therapy) approaches 
for treatment of diabetes.31 BARI-2D demonstrated no 
difference in all-cause mortality or major adverse cardio-
vascular events between individuals randomized to 
insulin sensitization as compared with insulin provision 
therapy. However, there are several important differences 
between our study and BARI-2D. First, and most impor-
tantly, over 40% of BARI-2D participants randomized to 
the insulin sensitization treatment arm were still treated 
with insulin or sulfonylureas during the study, and the 
most common treatment in the insulin provision arm 
was insulin. Therefore, the treatment comparison in 
BARI-2D diverged substantially from the present study. 
Second, the study populations differ: BARI-2D partic-
ipants were younger (62.4 vs 67.1 years of age), had a 
longer diabetes duration at baseline (10.4 vs 3.7 years), 
had higher baseline HbA1c (61 mmol/mol (7.7%) vs 46 
mmol/mol (6.4%)), were more likely to be taking insulin 
at baseline (28% vs none in our study), and were more 
likely to have had a prior MI (32% in BARI-2D, whereas 
our study was limited to individuals without a history of 
CAD). The BARI-2D population likely represented a less 
healthy population from a cardiometabolic perspective 
than the population in our VA observational study. Third, 
we observed a higher overall mortality rate than in BARI-
2D: 6.9% 2-year mortality in our study compared with 
13.3% 5-year mortality in BARI-2D. Taken together, the 
results of our study at minimum suggest caution specifi-
cally with sulfonylurea treatment in older individuals with 
well-controlled glycemia and newly diagnosed CAD, even 
if the BARI-2D study did not find evidence in support of 
a broader strategy of insulin sensitization compared with 
insulin provision in patients with diabetes and CAD. In 
sum, our study extends the existing literature by focusing 
on near-term safety and efficacy of oral diabetes treat-
ments in a specific high-risk population, thus providing 
evidence that may inform guideline-recommended 
diabetes treatment individualization.
Although we found increased mortality in individuals 
with CAD treated with sulfonylureas, our study does not 
elucidate the mechanism by which sulfonylurea use might 
lead to increased mortality or whether there are drug-spe-
cific associations with mortality within the sulfonylurea 
class. Among sulfonylureas in wide use in contemporary 
clinical practice, glyburide is associated more strongly 
with hypoglycemia than glipizide and glimepiride.32 33 In 
addition, glyburide, but not glimepiride or glipizide, is 
believed to limit ischemic preconditioning, suggesting 
drug-specific cardiac effects.11 28 34–36 In contrast to prior 
work, two recent studies argue against greater cardiovas-
cular toxicity of glyburide compared with glipizide. One, 
using a large national cohort in the UK, did not observe 
a difference in acute MI, ischemic stroke, cardiovascular 
death, or all-cause mortality when comparing different 
classes of sulfonylurea medications.37 In that study, 
however, those taking glyburide or glimepiride were at 
significantly increased risk of hypoglycemia compared 
with those taking glipizide, gliclazide, or tolbutamide.37 
A second study specifically evaluated the risk of sudden 
cardiac death or ventricular arrhythmia in US sulfony-
lurea users and found that glyburide was associated with a 
slightly lower risk of sudden cardiac death or ventricular 
arrhythmia than glipizide.38 In our study, the majority of 
participants (69%) used glipizide, and we did not observe 
a significant difference in mortality between glyburide 
users and those using glipizide or glimepiride. Thus, 
we conclude from our results that higher short-term 
mortality among sulfonylurea users compared with those 
taking non-sulfonylurea diabetes medications is a class 
effect, rather than a drug-specific effect, although we 
were unable to distinguish between direct cardiotoxicity, 
increased frequency and/or severity of hypoglycemia, or 
alternative explanations.
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Head-to-head studies demonstrating better outcomes 
with metformin than with sulfonylureas could not distin-
guish whether metformin has beneficial cardiovascular 
effects or if sulfonylureas have cardiotoxic affects.8 We 
did not observe significant differences in mortality 
between individuals treated with non-sulfonylurea medi-
cations (predominantly metformin) and those treated 
with no diabetes medications, but did observe increased 
mortality with sulfonylurea use. Assessing treatment-re-
lated outcomes in individuals with CAD is of particular 
importance since there is conflicting evidence regarding 
the cardiovascular safety of sulfonylureas, and diabetes 
and CAD co-occur frequently.11 23 24 28 34 39–42 Our study 
suggests a neutral effect of metformin use and increased 
harms associated with sulfonylurea treatment in individ-
uals with CAD and well-controlled glycemia, although we 
cannot determine if this is via a direct effect of sulfony-
lureas. Finally, by limiting our study population to those 
with well-controlled diabetes (and including baseline 
HbA1c and diabetes duration in the treatment propen-
sity model), we conclude that the association between 
medication category and mortality is independent of 
glycemic control. This is consistent with the findings of 
recent cardiovascular outcomes trials with newer diabetes 
medications that found associations between treatment 
and clinical outcomes independent of glycemia.3–7
Our study has important limitations. As with all obser-
vational studies, causal inference is limited. Our IPW 
approach cannot account for unmeasured factors associ-
ated with treatment choice. However, we included many 
relevant covariates, including comorbidities and other clin-
ical care variables associated with both treatment choice 
and outcomes, and demonstrated adequate confounder 
balance in our IPW sample. While we cannot exclude 
residual confounding, our results were stable in two sensi-
tivity analyses addressing imbalance in CKD/dialysis and 
variation across VA sites. Second, our study population 
was predominantly male; our results warrant validation in 
a cohort with greater representation of women, but there 
is no a priori reason to expect sex-specific associations 
between diabetes medications and mortality. Third, we 
were unable to determine if hypoglycemia was a mediator 
of the association between sulfonylurea use and mortality. 
Only severe hypoglycemia can be assessed using the VA 
electronic health record, but likely underestimates the 
frequency of clinically important hypoglycemic events. 
The rates of severe hypoglycemia necessitating clinical care 
were too low in our data to perform an adequately powered 
mediation analysis. Finally, by limiting the study population 
to individuals with well-controlled diabetes and on at most 
one oral medication, we diminished the generalizability of 
our results. Doing this, however, permitted better control 
of confounding and the potential to isolate the association 
between a single medication and outcomes, increasing 
internal validity.
Despite the limitations, our study has several clin-
ically relevant implications. First, we did not identify a 
short-term mortality benefit of metformin treatment in 
individuals with CAD for whom ongoing diabetes treat-
ment is needed. Second, diabetes medication choice, 
in addition to personalized glycemic control goals, is 
an important consideration in optimal individualized 
diabetes care; in this case, a diagnosis of CAD may warrant 
re-evaluation of diabetes treatment in individuals with 
good glycemic control. Third, recent randomized trials 
suggest that the members of the sodium-glucose co-trans-
porter-2 (SGLT-2) inhibitor and glucagon-like peptide-1 
(GLP-1) agonist classes of diabetes medication are associ-
ated with improved cardiovascular outcomes in high-risk 
individuals.3–7 However, the vast majority of participants 
in those studies had long-standing diabetes and were on 
one or more glycemic therapies to which the study drug 
(or placebo) was added.3–7 Head-to-head data of mono-
therapy with newer classes of medications compared 
with metformin and sulfonylureas are currently lacking. 
Additional evidence addressing the relative safety and 
efficacy of sulfonylureas compared with other diabetes 
medications in combination with metformin is expected 
from the Glycemia Reduction Approaches in Diabetes: 
A Comparative Effectiveness Study clinical trial, which is 
focused on identifying optimal secondary treatment for 
individuals who remain above their glycemic control 
goals on metformin alone.43 Finally, individuals with 
objectively determined CAD using sulfonylurea mono-
therapy had higher short-term mortality than those 
taking non-sulfonylurea medications. Our adjusted 
results in the full study population did not achieve statis-
tical significance, and causal conclusions are limited in 
this observational study. However, the magnitude of the 
association of sulfonylurea use with mortality and the 
improved statistical significance of the association in 
sensitivity analysis in a more well-matched study popu-
lation suggest sulfonylureas should be used with caution 
in those with CAD and diabetes. In this high-risk popula-
tion, providers may want to review sulfonylurea use and 
consider substituting metformin, if tolerated and not 
contraindicated, or newer diabetes agents with superior 
cardiovascular safety data.
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